Negative symptoms are defined as loss or reduction of otherwise present behaviors or functions in illness situation, and they have constituted an important aspect of schizophrenia. Although negative symptoms have usually been considered as a single entity, neurobiological investigations yielded discrepant results. To overcome challenges that derive from this discrepancy, researchers have proposed several approaches to structure negative symptoms into more homogenous constructs. Concept of persistent negative symptoms (PNS) is one of the proposed approaches, and includes both primary and secondary negative symptoms that persist after adequate treatment. PNS is relatively easy to assess, and by definition, more inclusive; yet it represents an unmet therapeutic need. Therefore, it is a target of several neurobiological and pharmacological studies. There are several structural and functional brain alterations associated with negative symptoms. On the other hand, neurocognitive investigations in patients with schizophrenia have revealed deficits in several domains that showed correlations with negative symptoms. There are several shared features between negative symptoms and neurocognitive deficits in schizophrenia such as prevalence rates, course through the illness, prognostic importance, and impact on social functioning. However, exact mechanisms behind the neurobiology of PNS and how it interacts with neurocognition remain to be explained. Earlier reviews on neuroimaging and neurocognitive correlates of PNS have been focused on studies with broadly defined negative symptoms that were selected by methodological closeness to PNS. In this review, we focus on neural correlates and neurocognitive associations of PNS, and we discuss PNS findings available to date.
Introduction
The multifaceted nature of schizophrenia has been a longstanding topic of interest for researchers. Several neurobiological, neuropsychological, or brain structural findings have been suggested to distinguish between symptom dimensions in schizophrenia, however, even a single symptom dimension itself does not always constitute a homogenous construct. 1 Therefore, working with a broadly defined negative symptom dimension in clinical trials, particularly for studies objecting treatment, poses several disadvantages. To overcome these, researchers have proposed several approaches that will structure negative symptoms into more homogenous constructs. By deconstructing negative symptoms into primary to illness and secondary to other factors, Carpenter et al 2 described a subgroup of patients who displayed primary or idiopathic enduring negative symptoms, referred to as deficit syndrome (DS). DS is separable from non-DS patients, possibly with different etiopathology, poor cognitive profile, and worse outcome. 3 Although DS criteria can successfully discriminate patients with primary enduring negative symptoms from non-DS patients, practically it has several challenges, especially when it is used for research purposes. For instance, considering that secondary negative symptoms are superimposed on primary negative symptoms in most cases, it is hard to distinguish negative symptoms due to identifiable causes (eg, extrapyramidal symptoms, depression or positive symptoms) from the primary ones without a careful longitudinal observation, ideally starting from early stages of disease. On the other hand, secondary negative symptoms that are resistant to treatment and interfering patient's life still carry a significant therapeutic importance. 4 Also, stringent nature of DS criteria has allowed to cover a small portion of patients who suffer from negative symptoms. Thus, persistent negative symptoms (PNS) have been proposed as an alternative in order to achieve a more homogenous group in clinical trials.
Definition of PNS includes negative symptoms that are primary to the illness, are secondary but have not responded to/resistant to regular antipsychotic treatment, interfere with the ability of the patient to perform normal role functions, persist during periods of clinical stability, and represent an unmet therapeutic need. 4 PNS criteria defined by Buchanan 5 outlined in Table 1 10 can be readily used. By definition, the extent of PNS is broader than that of DS. In the National Institute of Mental Health-Measurement and Treatment Research to Improve Cognition in Schizophrenia (NIMH-MATRICS) Consensus Statement, it is recommended to implement PNS criteria in clinical research design, especially in the ones targeting therapeutic interventions. 4 As indicated by the same consensus statement, 5 symptom domains including blunted affect, alogia, asociality, anhedonia, and avolition have been considered as the main constructs of negative symptoms, with possibly separate neurobiological underpinnings and treatment targets. 4, 11 Factor analytical studies repeatedly found that these domains have loaded on 2 factors, which considerably differed in clinical aspects like course of disease, premorbid functioning, and social-functional outcome, 12, 13 both in chronic 14, 15 and first episode psychosis (FEP) patients. 16 Anhedonia, asociality, and avolition constitute a subgroup representing avolition factor, whereas blunted affect and alogia constitute another subgroup representing expressive deficits factor.
It has been proposed that there are several structural and functional brain alterations associated with the negative symptoms either separately as a domain or as a general construct. 1, [17] [18] [19] [20] [21] [22] On the other hand, neurocognitive investigations in patients with schizophrenia have revealed deficits in several domains that showed correlations with negative symptoms. 23 There are several shared features between negative symptoms and neurocognitive deficits in schizophrenia such as prevalence rates, course through the illness, prognostic importance, and impact on social functioning. 24 However, exact mechanisms behind the neurobiology of PNS and how it interacts with neurocognition remain to be explained. Here in this review, we aim to focus on neural correlates and neurocognitive associations of PNS, and we will discuss findings available to date.
Neuroimaging Findings in Association With Persistent Negative Symptoms

Key Findings in Neuroimaging Research of Negative Symptoms
Neuroimaging research has yielded conflicting findings in terms of negative symptoms in schizophrenia, mostly due to differences in terminology, methodology, and patient selection criteria. 1 Although persistence of negative symptoms has been of interest in schizophrenia research for a long while, brain imaging studies focusing on current PNS conceptualization have gained importance, since recently NIMH MATRICS statement referred to PNS as an unmet therapeutic need and called scientists for action. 4 Earlier neuroimaging studies on persistence of negative symptoms have either used a different terminology for negative symptoms (eg, enduring negative symptoms or residual negative symptoms) or reviewed studies with negative symptoms that were not particularly named persistent but it was understood that they were persistent from the article content. 21, 25 From a general point of view, structural and functional alterations in frontal and temporal lobes have been repeatedly observed in neuroimaging research of schizophrenia, and particularly of negative symptoms. 21, [26] [27] [28] [29] [30] Earlier studies pointed out a functional association between negative symptoms and frontal lobar deficits, focusing on general hypofrontality as major neurobiological basis for negative symptoms [31] [32] [33] ; however, structural data were not able to support such a global association. 34, 35 More recently, gray matter reductions of certain frontal lobe components such as inferior and superior frontal gyri, medial and dorsolateral prefrontal cortices (PFC), orbitofrontal cortex (OFC) and anterior cingulate cortex (ACC) have been found to be in relation to presence and severity of negative symptoms, instead of a diffuse volumetric reduction. 17, [36] [37] [38] [39] Increases in gray matter volumes of these regions were also reported in association with negative symptoms in some other studies. 40 In addition to volumetric changes in frontal cortex, other cortical as well as subcortical regions were reported to be associated with broadly defined negative symptoms, including temporal cortex, parietal cortex, fusiform gyrus, thalamus, caudate, and amygdala. [41] [42] [43] [44] [45] [46] Besides volumetric investigations, cortical thickness analysis has become a widely used structural technique in schizophrenia research, typically resulted in thinning of frontotemporal area even in early stages of the disease. However, whether it is related to symptomatology or not is still a matter of debate. 47, 48 In addition to findings related to frontal cortex, relationship between cortico-striatal circuitry and negative symptoms has been demonstrated in numerous neuroimaging studies conducted with schizophrenia patients. [49] [50] [51] [52] [53] The interplay between striatum and frontal cortices, particularly medial PFC, OFC, and ACC, has taken a critical role in motivational processes such as reward anticipation, effort computation, value representation and goal directed actions, and abnormalities can be linked to schizophrenia. 54 Reductions in the activity of ventral striatum during reward processing has been observed in patients with schizophrenia [55] [56] [57] [58] [59] as well as high risk for psychosis populations. 60 However, opposite findings have also emerged. 61, 62 In their qualitative and quantitative review, Goghari et al 63 found a moderate relationship between decreased ventral striatum activity and negative symptoms in patients with schizophrenia. In the same study, other area moderately associated with negative symptoms was ventrolateral PFC. A meta-analysis of 23 studies revealed a significant bilateral hypoactivation of ventral striatum during reward anticipation task, and more weakly during reward feedback and prediction error. Abnormalities in left ventral striatum were more prominent as severity of negative symptoms increased. 64 Other studies reported decreases in activity of dorsal striatum, that is, caudate nucleus and putamen, in relation to negative symptoms of schizophrenia. 65, 66 Functional impairment in dorsolateral PFC is evident in schizophrenia, [67] [68] [69] yet, its association with negative symptoms remains vague. Some studies reported a reduced activation during reward prediction tasks that was associated with negative symptoms [70] [71] [72] [73] ; whereas, others either failed to report such relationship 65, 74 or proposed an association with cognitive dysfunction instead. 75, 76 As a part of reward processing system, dorsolateral PFC was suggested to take part in cognitive control and generation goal-directed behavior functions.
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Structural Neuroimaging Findings in PNS
A volumetric examination of 175 patients with schizophrenia, using voxel-based morphometry technique, identified significant reductions of gray matter density within prefrontal, limbic, paralimbic, temporal, and thalamic regions in patient group when compared with healthy controls. 45 In the same study, after dividing the patients into three subgroups as positive, negative, and disorganized based on a factor analysis of PANSS symptom dimensions, they found an association between negative symptoms and changes in OFC, medial frontal, lateral prefrontal and temporal regions bilaterally. Besides these cortical regions, limbic and subcortical structures such as left hemispheric caudate nucleus and thalamus were also found to be altered. It was noted that among all three, negative symptom subgroup had the greatest reductions in gray matter density with largest effect sizes. Although no clear reference was made in terms of persistence or longitudinal assessment of negative symptoms in negative subgroup, authors suggested that features of this group was comparable with criteria of primary and enduring negative symptoms. In another voxel-based morphometry study with 64 first-episode nonaffective psychosis patients, 16 of whom met PNS criteria, comparisons were made between patients with PNS, non-PNS, and healthy controls. 78 PNS patients had smaller gray matter volumes in right parahippocampal gyrus (extending into the superior temporal gyrus and fusiform gyrus than controls. Volume reductions were found in right frontal medial-orbital gyrus (extending into the inferior frontal gyrus) and right parahippocampal gyrus (extending into the fusiform gyrus) in PNS patients when compared to non-PNS group. Non-PNS versus healthy control comparison did not yield any difference. No significant correlation was found between frontal volumetric changes and severity of negative symptoms. Taken together, it was suggested that patients PNS might encompass a different neurobiological construct when compared with both non-PNS patients and healthy controls as localized frontal and possibly total temporal cortical volume reductions observed in PNS but not in other groups.
Bodnar et al 79 conducted additive cortical thickness analyses on same data, with an aim to reach a more detailed measurement of gray matter morphology by reflecting cortical laminar structure and integrity. In this study, PNS versus non-PNS comparisons led to a more prominent cortical thinning in patients with PNS in several regions including right parahippocampal gyrus and right orbitofrontal gyrus, which was in line with the previous study. 78 Furthermore, other structures such as bilateral anterior cingulate, right posterior cingulate, bilateral temporal, and fusiform gyri were identified thinner in patients with PNS, yet the widest thinning was found in the right superior temporal gyrus extending into the temporo-parietal junction. Comparisons with healthy controls yielded a diffuse cortical thinning in patients with PNS, most notable in right parahippocampal gyrus. In another cortical thickness study, age-related cortical thickness, and trajectory changes in relation to PNS were assessed longitudinally in 97 FEP patients and 48 healthy controls at 3 time points. 80 Patients were divided into 3 categories by presence and nature of negative symptoms, referred to as early PNS, secondary PNS, and non-PNS. Patients who thoroughly met the criteria for PNS were classified as early PNS (n = 21). Cortical thinning was more prominent within left inferior temporal/fusiform gyrus in patients with early PNS compared with nonearly PNS (ie, secondary PNS and non-PNS), and cortical thinning in the right middle temporal gyrus has persisted from baseline to second followup. Cortical thickness was found to be increased linearly with age in several frontal areas including left dorsolateral PFC and bilateral OFC; whereas quadratic effects were present in left dorsolateral PFC and right middle cingulate when compared with nonearly PNS, and in left inferior temporal cortices when compared with secondary PNS.
Hovington and Lepage 21 summarized temporal and specifically amygdala-hippocampal complex structural abnormalities associated with PNS, which yielded discrepant findings. Asymmetry of amygdala-hippocampal complex but not volume or shape was altered in patients in one study 81 ; whereas others indicated reductions in amygdala-hippocampal complex volume in patients with chronic schizophrenia, 18 and these changes were found to be stable for a 3-year period. 42 Correlations with symptom severity also differed between studies, some studies failed to demonstrate such a relationship. 18 In their most recent study, Makowski et al 82 adopted the same methodology from their previous study 80 to investigate age related changes of amygdala-hippocampus volume and surface area in FEP patients with or without persistent negative symptoms. It was reported that patients with early PNS had smaller volumes of left amygdala and right hippocampus when compared with other groups; and they showed negative interactions with age whereas patients with secondary PNS showed a totally different and positive age trajectory.
A recent Activation Likelihood Estimation meta-analysis of studies that fulfilled the PNS inclusion and exclusion criteria developed by Hovington and Lepage 21 revealed gray matter volume reductions in the bilateral medial frontal, the left precentral, the left middle frontal, and the bilateral parahippocampal gyri as well as the left anterior cingulate, the left caudate nucleus, the thalamus and the insula. 25 Gray matter volume reductions in prefrontal cortex appeared to be correlated with PNS.
In addition to gray matter, white matter abnormalities constituted another aspect of neuroimaging research of negative symptoms in patients with schizophrenia and gave rise to a greater rate of consistency when compared with gray matter findings. 21 According to Hovington and Lepage, 21 abnormalities in white matter as in the form of white matter integrity disruptions and reductions in volume were mostly located in the frontotemporal regions. However, these alterations were observed in chronic patients with unspecified or broadly defined negative symptoms. To clarify this, Hovington et al 83 investigated white matter microstructure in regions attributed to PNS. With the region-of-interest approach, analyses focused on fornix, bilateral uncinated fasciculus, superior longitudinal fasciculus, and the cingulum bundle. Although a white matter marker to dissociating PNS from non-PNS could not be identified, fractional anisotropy (FA) values were significantly lower in fornix of patients with PNS (n = 12) when compared with that of healthy subjects (n = 51); while PNS versus non-PNS (n = 52) comparison yielded lower FA values in the left superior longitudinal fasciculus in the PNS group. Symptom correlations in patient groups together pointed out a negative correlation between left uncinate fasciculus and severity of blunted affect; yet setting PNS group apart, decreased FA values in the right cingulum were moderately correlated with higher anhedonia-asociality scores on SANS.
Functional Neuroimaging Findings in PNS
Functional neuroimaging correlates of PNS has not been specifically investigated. Earlier studies included either DS or negative symptoms in general. In a systematic review on functional neuroanatomy of schizophrenia symptom dimensions, negative symptoms were found to be in relation with activities of ventrolateral prefrontal cortex and ventral striatum. 63 Recently, a positron emission tomography (PET) study revealed a modest cortical thinning and decreased glucose metabolism in thalamus and left anterior cingulate cortex of patient cluster B, a subgroup of schizophrenia patients whose negative symptoms persisted or worsened overtime. 84 Although a formal definition of PNS has not been made in the latter study, patients in cluster B had at least moderate severity of negative symptoms that persisted at the follow-up after 6 months. However, any role of confounding factors such as depression or extrapyramidal symptoms was not specified.
Neurocognitive Findings in Association With Persistent Negative Symptoms
Neurocognitive impairment is considered as one of the core aspects schizophrenia, reflecting brain pathology accompanying the disease process. 85 It has been suggested that neurocognitive disturbances may start as early as or even before the prodromal stage 86 and are present through the course of illness. 87 Although it has been a subject of controversy whether neurocognitive impairment is related to symptom groups of schizophrenia or not, evidence has revealed an association between certain cognitive deficits and negative symptoms. Myin-Germeys et al 88 suggested that there was a link between negative symptoms and cognitive impairment, which was not present between positive or affective symptom domains, and they both were related to poor clinical outcome. A systematic review of 58 studies and 5009 patients has revealed a modest association between cognitive deficits and negative symptoms, and higher correlations were found with verbal fluency. 89 Disorganized, but not positive or affective, symptoms were also associated with cognitive disturbances in the latter study. In another meta-analysis investigating the relationship between schizophrenia symptom dimensions and neurocognitive functioning, with an emphasis on executive functioning and sustained attention, found an inverse relationship between negative symptom severity and the performance on the Wisconsin Card Sorting Test (WCST) and the Continuous Performance Test. 90 However, the effect size of the correlations was modest at best. A similar conclusion was drawn by another meta-analysis for memory impairment, which showed a small association with negative symptoms. 91 Bora and Murray 86 focused on longitudinal studies with cognitive profiles of patients with FEP and ultra-high-risk for psychosis in comparison to healthy controls in their meta-analytical study and found an association between improvement in verbal working memory and executive functions and reductions in negative symptom severity in FEP. No such association was observed with other symptom subgroups.
Only recently studies addressing neurocognitive impairment in the context of PNS with currently established criteria have been published. An earlier study reflected a worse profile on Mini Mental Status Examination, Trial Making A-B and Verbal fluency in patients with persistently high negative symptoms compared those without. 92 Hovington et al 93 had investigated three memory domains in patients diagnosed as FEP with and without PNS for 1-year period and suggested that patients with PNS performed worse than the ones without PNS in verbal memory domain. Further investigations revealed a significant correlation with only alogia subdomain in FEP patients with PNS. In another study evaluating negative symptoms longitudinally for three years, diminished expressions, a subdomain of negative symptoms including alogia, was found to be related to certain neurocognitive domains at different time points; however, none of the relations persisted for the entire duration of the study. 94 Üçok and Ergül 95 found poorer scores on the WCST and trail making test in patients with PNS compared with non-PNS, representing abnormalities of executive functions and attention in their 2-year follow-up of 105 FEP patients. Another 235 patients with FEP were examined in terms of neurocognitive and social functioning. Executive function deficits were observed in PNS patients; higher PNS rates and poorer results on cognitive tests were found to be associated to early disease onset. 96 On the other hand, Malla et al 97 found that patients with and without PNS did not significantly differ on intellectual functioning or performances of memory, attention, processing speed or executive functions at baseline. A 3-year follow up for the persistence of negative symptoms in FEP patients included baseline measures of neurocognitive functions, which consisted of logical memory, visual reproduction, forward digit span, semantic fluency, modified WCST, and verbal intelligence; yet it failed to show any difference between patients with and without PNS on the neurocognitive domains examined. 98 Similarly, in another study with 345 FEP patients who were investigated in terms of PNS for 12 months, a cognitive battery that was made up of tests on processing speed, motor dexterity, verbal memory, and cognitive flexibility was employed at baseline and sixth month, but could not identify any difference between PNS and non-PNS patient groups.
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Conclusion
The concept of PNS includes both primary and secondary negative symptoms which have persisted after adequate treatment. 5 These are the symptoms that have a great impact on functional impairment 95, [97] [98] [99] [100] [101] ; yet represent an unmet therapeutic need. 4 Earlier reviews on neuroimaging and neurocognitive correlates of PNS have been focused on studies with broadly defined negative symptoms that were selected by methodological closeness to PNS criteria. 21, 25 Relatively few studies have compared schizophrenia patients with and without currently defined PNS criteria, in terms of white matter, gray matter, or neurocognitive alterations. At the time this review was conducted, there were no neuroimaging studies addressing functional alterations in patients with PNS, except one PET study, 84 which found decreased glucose metabolism in thalamus and left anterior cingulate cortex; but it did not explicitly define the PNS criteria used in the study or mention about secondary effects, such as depression or extrapyramidal symptoms. There appears to be a gap in the literature in this regard.
Brain imaging studies of PNS have resulted in inconsistent findings, involving changes in several frontal, temporal, limbic and subcortical regions, many of which were associated with corticostriatal reward network. 45, [78] [79] [80] 82, 83 It is notable that ventral striatum, a key component of reward network, did not appear to be altered in any of the studies. On the other hand, volumetric reductions in the gray matter of dorsal striatum, namely caudate nucleus, draw attention. 25, 45 This region has been shown to be related to motivation in both animal and human studies 102, 103 and volumetric alterations were observed in association with broadly defined negative symptoms. 104, 105 In line with this finding, dorsal caudate hypoactivity on functional magnetic resonance imaging during reward anticipation task was found to be related to persistent avolition. 66 Furthermore, gray mater volume reduction and cortical thinning were observed in parahippocampal gyrus in relation to PNS. 25, [78] [79] [80] 82 Parahippocampal gyrus has long been associated with memory formation in both preclinical and clinical subjects 106, 107 and gray matter reductions of this region have been demonstrated in schizophrenia, both in general and in the context of negative symptoms. 41, 108 Accordingly, Hovington et al 93 suggested that patients with PNS performed more poorly in verbal memory tasks when compared with non-PNS counterparts. However, other studies evaluating neurocognition in patients with PNS failed to achieve similar results. A neighboring region, fusiform gyrus was also associated with gray matter reductions in PNS studies. [78] [79] [80] Along with amygdala, fusiform gyrus constitutes an important part in facial emotion perception processes, which was found to be hypoactivated in patients with schizophrenia. 109 Emotion processing is counted as a domain of social cognitive processes, where the most consistent relationship with negative symptoms has been observed. 110, 111 Interestingly, being the region where most prominent thinning observed in one study, temporo-parietal junction has drawn growing attention for being involved in several social cognitive processes. [112] [113] [114] Therefore, it could be interpreted that cortical thinning in superior temporal gyrus extending into the temporoparietal junction 79 might be related to social functioning and social skill deficits in FEP patients with PNS. However, exact relationship between social cognition and PNS awaits further clarification.
Most studies covered in this review has been carried out in FEP patients. PNS prevalence in FEP populations was reported to be between 3.8% and 31.5% after the first year of follow-up. 95, [97] [98] [99] [100] [101] 115, 116 FEP may represent a critical stage to investigate negative symptoms, because it is less likely to be influenced by several potential confounding effects such as chronicity of disease process, long-term medication use. One caveat is that persistence of negative symptoms might not have reached stability in early phases of FEP. 95, 100 For this reason, frequent intervals or longer follow-ups may be required to assess PNS in FEP population.
Taken together, the heterogeneity between studies may arise from several factors, many yet to be explained. Diversity in the cognitive batteries and negative symptom scales can be counted among the factors that might have an impact on this discrepancy, which was also documented in literature. 87 Although majority of studies reviewed here based on Buchanan's definition of PNS, 5 they have differed in adapting PNS criteria, such as, in some studies at least moderate severity from total SANS score was taken into account, whereas in others, at least moderate severity from at least one negative symptom domain were required. 95,97-99, 101,116 Similarly, there exists heterogeneity in composition of patient groups and characteristics of negative symptoms that persisted. For instance, the most commonly observed persistent symptoms in the studies were avolition and anhedonia, 95, 101 and blunted affect. 99 In an attempt to reduce heterogeneity, future studies may be designed in a way that allows to assess persistence of a single symptom domain or subdomain separately. Novel tools, like BNSS 9 or MATRICS Consensus Cognitive Battery 117 seem promising to overcome at least some parts of this heterogeneity. Another issue is that, majority of studies was not designed to suggest a causal inference or a shared etiological factor about PNS and neurocognitive impairment. Several theoretical models were proposed to delineate possible intrinsic association between them; however, to confirm this, more studies are needed. 24 
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